Fig. 6: VIS832 treatment efficacy as monotherapy and in combination with btz in a murine model of disseminated human MM. | Blood Cancer Journal

Fig. 6: VIS832 treatment efficacy as monotherapy and in combination with btz in a murine model of disseminated human MM.

From: VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Fig. 6

a In vivo work plan. CB-17 SCID mice injected with MM1S-luc cells by i.v. route at day 0 were randomized on day 14 as the first day of dosing twice weekly with vehicle control (VC, PBS), VIS832 (4 mg/kg), btz (1 mg/kg), or combination of VIS832 and btz (n = 9 mice per group). Tumor burden was assessed by whole body BLI and quantified by IVIS imaging. Treatment was discontinued at day 53 (dosing phase), followed by a three-week washout period with end of study at day 73. b Group efficacy data. Disseminated tumor burden was reported as BLI ± SEM at each time point. Tumor growth was significantly inhibited starting at day 36 in VIS832 or btz vs. VC groups; the combination-treated vs. VC groups. (at Day 36, VIS832 vs. VC, P < 0.0001; btz vs. VC, P = 0.0001; VIS832 + btz vs. VC, P < 0.0001; VIS832 vs. VIS832 + btz, P < 0.0001; btz vs. VIS832 + btz, P < 0.0001; VIS832 vs. btz, P = 0.0004, by Tukey’s multiple comparison test). c Kaplan–Meier survival curves. The percentage of survival was defined as mice surviving to a pre-determined euthanasia criterion related to disease-related morbidity such as weight loss >20%, severely impaired central nervous system function, severely impaired movement, or loss of righting reflexes. VIS832 significantly increased the median overall survival of animals, and VIS832 with btz completely eradicated MM tumors, with all mice tumor-free (VC, 30d; VIS832 > 60d; btz, 42d; VIS832 + btz, >73d) (VIS832 vs. VC, P < 0.0001; btz vs. VC, P = 0.0004; VIS832 + btz vs. VC, P < 0.0001; VIS832 vs. VIS832 + btz, P < 0.02; btz vs. VIS832 + btz, P < 0.0001; VIS832 vs. btz, P = 0.02).

Back to article page